Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Flagstar Bank NA (FLG) vs Heron Therapeutics Inc (HRTX) Price & Performance

Flagstar Bank NATrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Flagstar Bank NA vs Heron Therapeutics Inc — how do they compare? Flagstar Bank NA trades at $14.23 (market cap $5.82B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Flagstar Bank NA is far larger — about 91.8× Heron Therapeutics Inc's market cap, and Flagstar Bank NA pays a 0.29% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

FLGHRTX
Market Cap
$5.82B$63.41M
Sector
FinancialsHealth
52-Week High
$15.36$1.49
52-Week Low
$10.72$0.32
Dividend Yield
0.29%
Enterprise Value
$161.31M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Flagstar Bank NA

Flagstar Bank (FLG) trades at $13.95, down 1.48% amid a bearish technical signal, though it remains profitable with a net income margin of 2.3% in 2026. Recent Q2 2026 earnings missed estimates, but the company announced a $250 million share repurchase program and continues dividend payments, reflecting confidence in its capital position. The stock trades below book value with a P/B of 0.76, offering a potential margin of safety.

The outlook is mixed: analyst consensus is bullish with a $16.85 price target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of growth initiatives, while downside could stem from further earnings misses or economic headwinds affecting the banking sector.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Flagstar Bank NA

Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.

Read more on FLG

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX